A Study of RC48-ADC for the Treatment of HER2-expression Metastatic Breast Cancer With Abnormal Activation of PAM Pathway
Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, single-arm phase II clinical trial to evaluate the efficacy and safety
of RC48 in metastatic human epidermal growth factor receptor 2 (HER2) expressing breast
cancer with abnormal activation of PAM pathway.
Phase:
Phase 2
Details
Lead Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences